Bioavailability is the measurement of the rate and extent that a therapeutically active drug reaches the systemic circulation and becomes available at the site of action. Possible methods for overcoming the poor bioavailability of drug are enhancement of solubility and dissolution rate. Poor water solubility of current active pharmaceutical ingredients (APIS) and new chemical entities (NCES) is a major problem in the development of pharmaceutical dosage forms. More than 40% of NCEs fall into Biopharmaceutical Classification System (BCS) class II category having dissolution rate limited bioavailability, whereas only 8% of new drug candidates have shown both high solubility and permeability. Various approaches to overcome the poor aqueous solubility of drug candidates have been investigated in drug research and development such as salt formation, prodrug formation, particle size reduction, complexation, micelles, microemulsions, nanoemulsions, nanosuspensions, solid-lipid nanoparticle and solid dispersion. Amorphous solid dispersions are one of the most promising strategies to improve the oral bioavailability of poorly water-soluble drugs with water-soluble carriers have been reduced theincidence of these problems and improved dissolution. A variety of excipients such as polymers and surfactants may be used to prepare and stabilize the amorphous form of a drug. Methods of preparing amorphous solid dispersions have been successfully used in commercial production are melt extrusion, spray drying, and rotary evaporation.
References not available.
Cite this article:
Kurrey (2016). Preparation of Amorphous Solid Dispersion of BCS Class II Drugs & Development of its Suitable Dosage Form for its Enhanced Solubility and Stability. Journal of Ravishankar University (Part-B: Science), 29(1), pp.80-81.